The estimated Net Worth of Barry P Flannelly is at least $16.3 million dollars as of 15 July 2024. Mr. Flannelly owns over 1,306 units of Incyte stock worth over $3,664,191 and over the last 10 years he sold INCY stock worth over $7,196,990. In addition, he makes $5,442,940 as Executive Vice President and General Manager - US at Incyte.
Barry has made over 21 trades of the Incyte stock since 2016, according to the Form 4 filled with the SEC. Most recently he sold 1,306 units of INCY stock worth $83,832 on 15 July 2024.
The largest trade he's ever made was selling 43,993 units of Incyte stock on 8 April 2022 worth over $3,672,976. On average, Barry trades about 2,780 units every 43 days since 2014. As of 15 July 2024 he still owns at least 58,042 units of Incyte stock.
You can see the complete history of Mr. Flannelly stock trades at the bottom of the page.
Barry P. Flannelly is Executive Vice President and General Manager - US of Incyte Corporation. He has served as Executive Vice President and General Manager US since June 2015 and joined Incyte as Executive Vice President, Business Development and Strategic Planning in August 2014. Prior to joining Incyte, he served as Chief Executive Officer of OSS Healthcare Inc., a biotechnology start-up company, from August 2013 to July 2014. He served as Vice President, Global Product Strategy and Commercial Planning of Nektar Therapeutics, a biopharmaceutical company, from April 2011 until April 2013, and as Senior Vice President, Commercial, of Onyx Pharmaceuticals, Inc., a biopharmaceutical company, from August 2008 until January 2011. Prior thereto, Dr. Flannelly held key positions at biopharmaceutical and pharmaceutical companies such as Abraxis BioScience, Inc. and Novartis. Dr. Flannelly earned his doctorate in pharmacy from the University of Maryland, School of Pharmacy, his master’s degree in business administration from the University of Baltimore, and his B.S. degree in Pharmacy from Massachusetts College of Pharmacy.
As the Executive Vice President and General Manager - US of Incyte, the total compensation of Barry Flannelly at Incyte is $5,442,940. There are 3 executives at Incyte getting paid more, with Herve Hoppenot having the highest compensation of $15,151,200.
Barry Flannelly is 62, he's been the Executive Vice President and General Manager - US of Incyte since 2015. There are 7 older and 19 younger executives at Incyte. The oldest executive at Incyte Corp. is Pamela M. Murphy, 70, who is the VP of Investor Relations & Corp. Communications.
Barry's mailing address filed with the SEC is 1801 AUGUSTINE CUT-OFF, , WILMINGTON, DE, 19803.
Over the last 21 years, insiders at Incyte have traded over $114,417,378 worth of Incyte stock and bought 24,211,970 units worth $713,884,116 . The most active insiders traders include Bros. Advisors Lp14159, L.P..., Bros. Advisors Lp667, L.P.B... et Brothers Life Sciences Capi.... On average, Incyte executives and independent directors trade stock every 14 days with the average trade being worth of $4,355,654. The most recent stock trade was executed by Steven H Stein on 12 August 2024, trading 11,608 units of INCY stock currently worth $703,793.
incyte is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics, primarily for oncology. our vision is to become a leader in the development and delivery of novel drugs for serious unmet medical needs. we have established multiple collaborations with major pharmaceutical companies to support the clinical development and global commercialization of several of our compounds. the incyte corporate headquarters is located in wilmington, delaware, and more than 625 employees comprise our experienced management, discovery, clinical development and commercial teams. our assets, experience and prior success in bringing important new drugs to market put us in a strong position to make a difference by improving the lives of patients and building sustainable value for our shareholders. for more information about incyte, please visit our corporate website at www.incyte.com.
Incyte executives and other stock owners filed with the SEC include: